FABP4 and metabolic dysfunction-associated steatohepatitis: These findings are consistent with previous studies that demonstrated a significant positive association between elevated FABP4 levels and a cluster of metabolically driven low-grade chronic inflammation, including iron accumulation, type 2 diabetes mellitus, insulin resistance, atherogenic dyslipidemia, nonalcoholic steatohepatitis, and cardiovascular dysfunctions [13, 21–23].